

## Søknadsinformasjon

---

<b>Utlysning</b>	Nordic Cancer Union Research Grant, 2015
<b>Søknad</b>	A Randomized Phase II Study Comparing Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small-Cell Lung Cancer
<b>Søknadsid</b>	176352
<b>Innsendt av</b>	Bjørn H. Grønberg

## Oppgave: Progress report

---

<b>Tilordnet</b>	Bjørn H. Grønberg
<b>Status</b>	Løst
<b>Opprettet</b>	10.02.2017

## RAPPORT

---

### **Briefly describe the project in a language understandable to non-scientists**

Concurrent chemo- and radiotherapy is the standard treatment of small-cell lung cancer if all lesions can be included in a tolerable radiotherapy field. 25% of patients are cured. Thus, there is a need of better treatment. Some data indicate that higher radiotherapy-doses are more effective, but this has not been tested in a prospective randomized trial. In this study, patients with limited disease small-cell lung cancer are randomized to receive either standard radiotherapy (45 Gy in 30 fractions) or high-dose radiotherapy (60 Gy in 40 fractions). The aim is to compare survival and tolerability. The study is conducted in collaboration between Norwegian, Swedish and Danish Hospital.

### **Summarize the major findings of the project**

Currently, 116/154 patients are enrolled. With the current enrollment rate, we expect to include the last patient during Q3 2017, which is >2 years ahead of schedule. So far, the high-dose radiotherapy has been possible to deliver in all except 3 patients. We do not have any indications of more severe toxicity in the high-dose arm.

### **Describe how the project has increased our knowledge of the prevention, cause and/or cure for cancer**

The primary endpoint is 2 year survival. We expect to meet this endpoint Q3 2019.

### **Outline how Nordic cooperation has added value to this project**

Participation from leading hospitals in the Nordic countries has increased the enrollment rate. Furthermore, a common plan for diagnosis, staging and treatment of this patient cohort has been established. In addition to ensure implementation of recommended treatment, conducting the study together also facilitates future collaboration.

### **Brief overview of expenditures for last year** 1 vedlegg (Regnskap for 2016 THORA NCU.docx)